NCT03901469 2025-10-07
TNBC
Zenith Epigenetics
Phase 2 Terminated
Clinical Trials
13 trialsNCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03148795 2024-04-05
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 2 Completed
NCT04690855 2023-12-04
TARA
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03565991 2023-09-25
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Pfizer
Phase 2 Terminated
NCT02401347 2023-02-21
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Stanford University
Phase 2 Completed
NCT02921919 2022-08-24
Open-Label Extension and Safety Study of Talazoparib
Pfizer
Phase 2 Completed
NCT02282345 2022-07-06
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03499353 2021-11-09
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Pfizer
Phase 2 Terminated
NCT03377556 2021-06-23
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02034916 2019-10-14
ABRAZO
Pfizer
Phase 2 Terminated